 |
|
Human Immunodeficiency Virus Counseling, Testing, Referral, and Partner Notification ServicesA Cost-Benefit Analysis
David R. Holtgrave, PhD;
Ronald O. Valdiserri, MD, MPH;
A. Russell Gerber, MD;
Alan R. Hinman, MD, MPH
Arch Intern Med. 1993;153(10):1225-1230.
Abstract
| |
Background
The Centers for Disease Control and Prevention (Atlanta, Ga) annually provides more than $100 million in funding to states, territories, and cities for the provision of human immunodeficiency virus (HIV) counseling, testing, referral, and partner notification (CTRPN) services. Given the size of this expenditure, it is important to consider the net benefits of this program activity. We compared the economic costs and benefits of publicly funded HIV CTRPN services.
Methods
Standard methods for cost-benefit analysis were used. A societal perspective was employed. Major assumptions used in the base-case analysis included the following: (1) without public funding, the HIV CTRPN services would not be provided; (2) for every 100 HIV-seropositive persons identified and reached by CTRPN services, at least 20 new HIV infections are averted; and (3) for every $100 spent on direct and indirect costs of CTRPN services, approximately another $60 is spent on the ancillary costs of alerting people to HIV issues and CTRPN service availability. Sensitivity analyses were performed to explore the robustness of base-case results to these and other changes in model assumptions.
Results
Under base-case assumptions, the combined direct, indirect, and ancillary costs of the CTRPN program in 1990 dollars were $188 217 600. At a 6% discount rate, the estimated economic benefits of this expenditure are $3 781 918 000. The resultant benefit-cost ratio is 20.09. Sensitivity analyses showed that the benefit-cost ratio is greater than 1 for all considered cases.
Conclusions
This cost-benefit analysis strongly suggests that publicly funded CTRPN services result in a net economic gain to society.
(Arch Intern Med. 1993;153:1225-1230)
Author Affiliations
From the National Center for Prevention Services, Centers for Disease Control and Prevention, Atlanta, Ga.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations
Barham et al.
Sex. Transm. Infect. 2007;83:441-446.
ABSTRACT
| FULL TEXT
Trends in Human Immunodeficiency Virus Seroincidence among Street-Recruited Injection Drug Users in San Francisco, 1987-1998
Kral et al.
Am J Epidemiol 2003;157:915-922.
ABSTRACT
| FULL TEXT
Economic Evaluation of Safer Choices: A School-Based Human Immunodeficiency Virus, Other Sexually Transmitted Diseases, and Pregnancy Prevention Program
Wang et al.
Arch Pediatr Adolesc Med 2000;154:1017-1024.
ABSTRACT
| FULL TEXT
Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago
Immergluck et al.
Pediatrics 2000;105:54e-54.
ABSTRACT
| FULL TEXT
Economic Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns With Zidovudine: Implications for HIV Screening
Mauskopf et al.
JAMA 1996;276:132-138.
ABSTRACT
Threshold Analysis and Programs for Prevention of HIV Infection
Holtgrave and Qualls
Med Decis Making 1995;15:311-317.
ABSTRACT
The Cost-effectiveness of Voluntary Counseling and Testing of Hospital Inpatients for HIV Infection
Lurie et al.
JAMA 1994;272:1832-1838.
ABSTRACT
HIV prevention programs
Holtgrave and Qualls
Science 1994;266:16-16.
Evaluating Behavioral Interventions: Need for Randomized Controlled Trials-Reply
Peterman and Aral
JAMA 1994;271:1318-1318.
ABSTRACT
Evaluating Behavioral Interventions: Need for Randomized Controlled Trials
Gerber et al.
JAMA 1994;271:1317-1318.
ABSTRACT
The Cost-effectiveness of HIV Testing of Physicians and Dentists in the United States
Phillips et al.
JAMA 1994;271:851-858.
ABSTRACT
|
